Coordination-driven FBXW7 DNAzyme-Fe nanoassembly enables a binary switch of breast cancer cell cycle checkpoint responses for enhanced ferroptosis-radiotherapy
Source abstract
Abstract
Radiotherapy is a mainstream modality for breast cancer treatment that employs ionizing radiation (IR) to damage tumor cell DNA and elevate ROS stress, which demonstrates multiple clinically-favorable advantages including localized treatment and low invasiveness. However, breast cancer cells may activate the p53-mediated cell cycle regulation in response to radiotherapy to repair IR-induced cellular damage and facilitate post-treatment survival. F-Box and WD Repeat Domain Containing 7 (FBXW7) is a promoter of p53 degradation and critical nexus of cell proliferation and survival events. Herein, we engineered a cooperative radio-ferroptosis-stimulatory nanomedicine through coordination-driven self-assembly between ferroptosis-inducing Fe2+ ions and FBXW7-inhibiting DNAzymes and further modification of tumor-targeting dopamine-modified hyaluronic acid (HA). The nanoassembly could be selectively internalized by breast cancer cells and disintegrated in lysosomes to release the therapeutic payload. DNAzyme readily abolishes FBXW7 expression and stabilizes phosphorylated p53 to cause irreversible G2 phase arrest for amplifying post-IR tumor cell apoptosis. Meanwhile, the p53 stabilization also inhibits the SLC7A11-cystine-GSH axis, which combines with the IR-upregulated ROS levels to amplify Fe2+-mediated ferroptotic damage. The DNAzyme-Fe-HA nanoassembly could thus systematically boost the tumor cell damaging effects of IR, presenting a simple and effective approach to augment the response of breast cancer to radiotherapy. STATEMENT OF SIGNIFICANCE: To overcome the intrinsic radioresistance in breast cancer, we prepared co-assembly of Fe2+ and FBXW7-targeted DNAzymes and modified surface with dopamine conjugated hyaluronic acid (HA), which enabled tumor-specific FBXW7-targeted gene therapy and ferroptosis therapy in IR-treated breast cancers. The nanoassembly could be activated in acidic condition to release the therapeutic contents. Specifically, the DNAzymes could selectively degrade FBXW7 mRNA in breast cancer cells to simultaneously induce accumulation of p53 and retardation of NHEJ repair, eventually inducing irreversible cell cycle arrest to promote apoptosis. The p53 stabilization would also inhibit the SLC7A11/GSH/GPX4 axis to enhance Fe2+ mediated ferroptosis. These merits could act in a cooperative manner to induce pronounced tumor inhibitory effect, offering new approaches for tumor radiosensitization in the clinics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Epigenetics and DNA Methylation · Ferroptosis and cancer prognosis · RNA modifications and cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Nanoscale metal-organic layers for radiotherapy-radiodynamic therapy10.1021/jacs.8b11593 ↗
3. Plasmonic AuPt@CuS heterostructure with enhanced synergistic efficacy for radiophotothermal therapy10.1021/jacs.1c06652 ↗
4. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy10.1038/s41392-021-00648-7 ↗
5. Mutational signatures are jointly shaped by DNA damage and repair10.1038/s41467-020-15912-7 ↗
6. Multiple biochemical properties of the p53 molecule contribute to activation of polymerase iota-dependent DNA damage tolerance10.1093/nar/gkaa974 ↗
7. The multiple mechanisms that regulate p53 activity and cell fate10.1038/s41580-019-0110-x ↗
8. Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT10.1172/JCI80402 ↗
9. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interact ion promotes the growth of p53 wild-type breast cancers by degrading p5310.1038/s41418-021-00762-7 ↗
10. p53 regulates a G2 checkpoint through cyclin B110.1073/pnas.96.5.2147 ↗
11. FBXW7: a critical tumor suppressor of human cancers10.1186/s12943-018-0857-2 ↗
12. FBXW7 confers radiation survival by targeting p53 for degradation10.1016/j.celrep.2019.12.032 ↗
13. FBXW7 Facilitates nonhomologous end-joining via K63-linked polyubiquitylation of XRCC410.1016/j.molcel.2015.12.010 ↗
14. Loss of FBXW7 correlates with increased IDH1 expression in glioma and enhances IDH1-mutant cancer cell sensitivity to radiation10.1158/0008-5472.CAN-21-0384 ↗
15. The WD40 domain of FBXW7 is a poly (ADP-ribose)-binding domain that mediates the early DNA damage response10.1093/nar/gkz058 ↗
16. p53 dynamics vary between tissues and are linked with radiation sensitivity10.1038/s41467-021-21145-z ↗
17. Designing core-shell gold and selenium nanocomposites for cancer radiochemotherapy10.1021/acsnano.7b01346 ↗
18. A DNA-based nanocarrier for efficient gene delivery and combined cancer therapy10.1021/acs.nanolett.7b04812 ↗
19. Ferroptosis as a p53-mediated activity during tumour suppression10.1038/nature14344 ↗
20. A biologically stable DNAzyme that efficiently silences gene expression in cells10.1038/s41557-021-00645-x ↗
21. DNAzyme-functionalized nanomaterials: recent preparation, current applications, and future challenges
22. A general purpose RNA-cleaving DNA enzyme10.1073/pnas.94.9.4262 ↗
23. Cell surface engineering using DNAzymes: metal ion mediated control of cell–cell interactions10.1021/jacs.1c00060 ↗
24. A Synergistic DNA-polydopamine-MnO2 nanocomplex for near-infrared-light-powered DNAzyme-mediated gene therapy10.1021/acs.nanolett.1c01727 ↗
25. Carrier-free hybrid DNA nanoparticles for light-induced self-delivery of functional nucleic acid enzymes10.1021/acsnano.0c10045 ↗
26. Herpesvirus-mimicking DNAzyme-loaded nanoparticles as a mitochondrial DNA stress inducer to activate innate immunity for tumor therapy10.1002/adma.202204585 ↗
27. Visualized and cascade-enhanced gene silencing by smart DNAzyme-graphene nanocomplex10.1007/s12274-020-2826-5 ↗
28. Reversing the negative effect of adenosine A1 receptor-targeted immuno metabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme10.1016/j.nantod.2022.101722 ↗
29. DNAzyme-loaded metal-organic frameworks (MOFs) for self-sufficient gene therapy10.1002/anie.201902714 ↗
30. A bimetallic metal-organic framework encapsulated with dnazyme for intracellular drug synthesis and self-sufficient gene therapy10.1002/anie.202016442 ↗
31. Self-assembled copper-amino acid nanoparticles for in situ glutathione "AND" H2O2 sequentially triggered chemodynamic therapy10.1021/jacs.8b08714 ↗
32. Recent developments in G-quadruplex binding ligands and specific beacons on smart fluorescent sensor for targeting metal ions and biological analytes10.1021/acssensors.2c00992 ↗
33. Self-assembly of copper-DNAzyme nanohybrids for dual-catalytic tumor therapy10.1002/anie.202101744 ↗
34. A DNA nanocomplex containing cascade DNAzymes and promoter-Like Zn-Mn-ferrite for combined gene/chemo-dynamic therapy10.1002/anie.202113619 ↗
35. Engineering multifunctional DNA hybrid nanospheres through coordination-driven self-assembly10.1002/anie.201810735 ↗
36. A Biomimetic Coordination Nanoplatform for Controlled Encapsulation and Delivery of Drug-Gene Combinations10.1002/anie.201903417 ↗
37. One-Step Synthesis of Single-Stranded DNA-Bridged Iron Oxide Supraparticles as MRI Contrast Agents10.1021/acs.nanolett.0c04825 ↗
38. Ferroptosis: an iron-dependent form of nonapoptotic cell death10.1016/j.cell.2012.03.042 ↗
39. NIR-Actuated remote activation of ferroptosis in target tumor cells through a photothermally responsive iron-chelated biopolymer nanoplatform10.1002/anie.202016872 ↗
40. Acidity-activatable dynamic nanoparticles boosting ferroptotic cell death for immunotherapy of cancer10.1002/adma.202101155 ↗
41. A dopamine-precursor-based nanoprodrug for in-situ drug release and treatment of acute liver failure by inhibiting NLRP3 inflammasome and facilitating liver regeneration10.1016/j.biomaterials.2020.120573 ↗
42. Serially pH-modulated hydrogels based on boronate ester and polydopamine linkages for local cancer therapy10.1021/acsami.0c16199 ↗
43. Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress10.1038/s41467-020-20243-8 ↗
44. Multifaceted mechanisms mediating cystine starvation-induced ferroptosis10.1038/s41467-021-25159-5 ↗
45. Surface coating of pulmonary siRNA delivery vectors enabling mucus penetration, cell targeting, and intracellular radical scavenging for enhanced acute lung injury therapy10.1021/acsami.1c23069 ↗
46. An integrated strategy for rapid hemostasis during tumor resection and prevention of postoperative tumor recurrence of hepatocellular carcinoma by antibacterial shape memory cryogel10.1002/smll.202101356 ↗
47. Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells10.1126/sciadv.aax1346 ↗
48. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
49. Blocking glutathione regeneration: Inorganic NADPH oxidase nanozyme catalyst potentiates tumoral ferroptosis10.1016/j.nantod.2022.101574 ↗
50. A solid lipid coated calcium peroxide nanocarrier enables combined cancer chemo/chemodynamic therapy with O2/H2O2 self-sufficiency10.1016/j.actbio.2020.12.036 ↗
51. Oligo hyaluronan-coated silica/hydroxyapatite degradable nanoparticles for targeted cancer treatment10.1002/advs.201900716 ↗
52. Nonviolent self-catabolic DNAzyme nanosponges for smart anticancer drug delivery10.1021/acsnano.9b01589 ↗
53. Activatable biomineralized nanoplatform remodels the intracellular environment of multidrug-resistant tumors for enhanced ferroptosis/apoptosis therapy10.1002/smll.202102269 ↗
54. ATP-dependent modulation of MgtE in Mg2+ homeostasis10.1038/s41467-017-00082-w ↗
55. Upconversion luminescence-boosted escape of DNAzyme from endosomes for enhanced gene-silencing efficacy10.1002/anie.202206485 ↗
56. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma10.1172/JCI99032 ↗
57. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer10.1038/s41586-021-03539-7 ↗
58. A nonferrous ferroptosis-like strategy for antioxidant inhibition-synergized nanocatalytic tumor therapeutics10.1126/sciadv.abj8833 ↗
59. Self-adaptive single-atom catalyst boosting selective ferroptosis in tumor cells10.1021/acsnano.1c08464 ↗
60. Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy10.1021/acsnano.1c08664 ↗
61. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation10.1038/s41467-021-21841-w ↗
62. Ethyl carbamate triggers ferroptosis in liver through inhibiting GSH synthesis and suppressing Nrf2 activation10.1016/j.redox.2022.102349 ↗
63. Melatonin sensitizes human breast cancer cells to ionizing radiation b y downregulating proteins involved in double-strand DNA break repair10.1111/jpi.12205 ↗
64. Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors10.1021/jacs.2c10177 ↗
65. Tumor-microenvironment-activated in situ self-assembly of sequentially responsive biopolymer for targeted photodynamic therapy10.1002/adfm.202000229 ↗
66. Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol10.1093/annonc/mdx488 ↗